ImmunoGen, Inc. (IMGN) financial statements (2023 and earlier)

Company profile

Business Address 830 WINTER ST
WALTHAM, MA 02451
State of Incorp. MA
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
6/30/2016
6/30/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments479294176262267245278
Cash and cash equivalents479294176262267245278
Receivables7092525
Inventory, net of allowances, customer advances and progress billings    113
Inventory    113
Deferred costs     21
Other undisclosed current assets14302414355
Total current assets:500324209279276255292
Noncurrent Assets
Operating lease, right-of-use asset121416
Property, plant and equipment56713152316
Deferred costs     64
Other noncurrent assets91144431
Total noncurrent assets:26312617183222
TOTAL ASSETS:526355235295295287314
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities47433344373328
Accounts payable181010119128
Accrued liabilities23291421171011
Employee-related liabilities5591211118
Deferred revenue44290
Debt 23    
Deferred revenue and credits1140
Contract with customer, liability0
Other undisclosed current liabilities1048412618158
Total current liabilities:1011227771566136
Noncurrent Liabilities
Long-term debt and lease obligation15192422100 
Long-term debt, excluding current maturities  222100 
Operating lease, liability151922
Liabilities, other than long-term debt4983128851033045
Deferred revenue and credits992641
Deferred revenue4881127
Contract with customer, liability80
Other liabilities1314444
Other undisclosed noncurrent liabilities354182127152178198
Total noncurrent liabilities:99143234214257308243
Total liabilities:200266311284313369279
Stockholders' equity
Stockholders' equity attributable to parent32690(76)11(18)(82)35
Common stock2221111
Additional paid in capital1,7951,4191,2101,1931,009771743
Accumulated deficit(1,471)(1,332)(1,287)(1,183)(1,029)(854)(709)
Total stockholders' equity:32690(76)11(18)(82)35
TOTAL LIABILITIES AND EQUITY:526355235295295287314

Income statement (P&L) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
6/30/2016
6/30/2015
Revenues7013282531156086
Revenue, net4419
Cost of revenue
(Cost of Goods and Services Sold)
    (1)(1)(1)
Gross profit:7013282531145984
Operating expenses(195)(155)(174)(215)(174)(185)(140)
Other undisclosed operating income    111
Operating loss:(125)(22)(92)(161)(59)(125)(54)
Nonoperating income (expense)(1)15330(1)
Investment income, nonoperating0144100
Other nonoperating income (expense)(1)01(1)1(0)(1)
Interest and debt expense(0)(0)(0)(0)(26)  
Other undisclosed loss from continuing operations before equity method investments, income taxes      (5)
Loss from continuing operations before equity method investments, income taxes:(126)(21)(87)(158)(82)(125)(61)
Other undisclosed loss from continuing operations before income taxes(13)(23)(17)(11)(14)(20) 
Net loss available to common stockholders, diluted:(139)(44)(104)(169)(96)(145)(61)

Comprehensive Income ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
6/30/2016
6/30/2015
Net loss:(139)(44)(104)(169)(96)(145)(61)
Comprehensive loss, net of tax, attributable to parent:(139)(44)(104)(169)(96)(145)(61)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: